Rhinomaxil

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rhinomaxil

Property Description
Active ingredient Beclometasone dipropionate
Form Metered-dose nasal spray
Pharmacological class Corticosteroid (Glucocorticoid)
Common purpose Reduction of nasal swelling and inflammation
Origin Synthetic

Rhinomaxil is a synthetic, localized-action medicine containing the active ingredient beclometasone dipropionate, which is structurally classified as a Glucocorticoid and belongs to the powerful Corticosteroid pharmacological class. This preparation is a single active ingredient product specifically designed to address inflammation and allergic processes within the nasal passages.

What Type of Medicine is Rhinomaxil?

Rhinomaxil is an intranasal medication that uses a synthetic form of a glucocorticoid to control inflammation in the nasal lining. The primary component, beclometasone dipropionate, acts as a prodrug that rapidly converts to its active, functional metabolite upon localized application. The beclometasone base is recognized for its potent local action, ensuring effective management of nasal irritation. As a corticosteroid, its mechanism is fundamentally distinct from simple decongestants or standard oral antihistamines.

Composition and Physical Form

The core component is beclometasone dipropionate, delivered to the nasal passages as a metered-dose nasal spray. This pharmaceutical form is an aqueous suspension (water-based medium), which ensures the active substance is uniformly and effectively pulverized onto the mucosal surface. The choice of a nasal spray formulation, intended for topical administration, is strategic: it concentrates the medication's potent anti-inflammatory activity precisely at the required site, ensuring efficacy while promoting minimal systemic exposure, as nasal delivery focuses the effect locally.

General Purpose and Physiological Effect

The general purpose of Rhinomaxil is to reduce persistent swelling and irritation in the nose by controlling the underlying inflammatory cascade, such as that caused by severe seasonal pollen exposure. Its glucocorticoid action enables it to stabilize cells responsible for initiating the inflammatory cycle and inhibit the production of numerous mediators, such as pro-inflammatory cytokines, providing a significant anti-allergic effect. By dampening this persistent inflammatory process at the source, the medicine helps alleviate chronic congestion and discomfort, facilitating clearer, easier nasal breathing.

What side effects are possible with Rhinomaxil?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety constraints for Rhinomaxil (Beclomethasone Dipropionate Nasal Aerosol), strictly based on governmental regulatory sources. The safety profile is characterized by common local effects and rare, but serious, systemic or immunological reactions.


Adverse Reactions by Frequency and System

The majority of documented adverse reactions are local and classified by frequency based on clinical trials:

  • Common Reactions (ge 1% incidence): Includes Epistaxis (nosebleeds), Headache, Nasal discomfort, and Nasal Ulceration.
  • Infections: Localized infection of the nose and pharynx with Candida albicans (thrush) is a documented risk.

Serious and Clinically Significant Safety Concerns

While rare, the following serious or clinically significant effects have been reported in official labeling:

  • Systemic Effects: Potential for Adrenal Suppression (HPA axis effect) exists, primarily with prolonged use at higher than recommended doses. This risk is generally lower than with oral corticosteroids.
  • Immunological Reactions: Cases of Hypersensitivity Reactions, including Anaphylaxis, Angioedema, and Urticaria, are documented.
  • Eye Disorders: Long-term use may require monitoring for the potential development of Glaucoma or Cataracts.

Safety Restrictions and Population Notes

  • Contraindications: Rhinomaxil is contraindicated in individuals with a history of hypersensitivity to any component of the formulation.
  • Nasal Injury: Use should be avoided in patients with recent nasal ulcers, surgery, or trauma due to concerns over impaired wound healing.
  • Pediatric Use: The potential for growth retardation in children and adolescents requires regular monitoring of growth velocity during treatment.

Overdose and Emergency Response

The official regulatory profile for Rhinomaxil overdose centers on the risks associated with prolonged administration of high doses, rather than acute, single-event toxicity. Overdose manifestations are defined by the systemic effects of the glucocorticoid, which can lead to Hypercorticism, a state that may present with Cushingoid features, menstrual irregularities, and the development of cataracts or glaucoma. The most significant physiological finding documented is Adrenal Suppression (HPA axis suppression), which requires medical attention due to the risk of Adrenal Insufficiency during times of stress or withdrawal.

When to Seek Help

Regulators mandate that individuals seek immediate medical attention or call the national Poison Help line for suspected exposure exceeding the recommended dose. Immediate contact with emergency services is required for any signs of severe systemic hypersensitivity, such as sudden swelling of the face, tongue, or throat, or difficulty breathing. Management strategies involve symptomatic and supportive treatment, including the mandated need to discontinue the medication slowly if signs of systemic effects are observed. Special regulatory notes highlight the risk of reduction in growth velocity for pediatric patients on long-term high-dose therapy.

Therapeutic Uses of Rhinomaxil

What Rhinomaxil Treats: Main Uses and Benefits


The primary therapeutic role of Rhinomaxil (beclometasone dipropionate nasal spray) is to provide localized support for symptoms related to inflammatory or irritative states within the nasal passages. This medication is applied in clinical settings that involve acute or unstable symptom patterns, and short-term symptom management is appropriate across several key domains. It is commonly used to help with conditions presenting with systemic or localized discomfort, such as seasonal allergic rhinitis, perennial allergic rhinitis, and non-allergic (vasomotor) rhinitis.

Rhinomaxil is relevant for managing symptom clusters that may become intense or disruptive, including severe nasal congestion, excessive rhinorrhea (runny nose), frequent sneezing fits, and nasal itching. By managing these distressing manifestations, the medication provides support that helps ease the overall symptom burden for individuals facing recurrent or chronic nasal issues. It is commonly used for chronic daily control of symptoms or as a therapeutic measure following surgery to help prevent the regrowth of nasal polyps (polypectomy).

“This medication provides support that helps ease the overall symptom burden for individuals facing recurrent or chronic nasal issues.”

This application is commonly used across patient groups, including adults and children, to help maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Support for Nasal Congestion
Rhinomaxil is applied in addressing symptoms related to physical discomfort, such as nasal obstruction, when symptoms may intensify temporarily.

Regulatory References

  1. NIH DailyMed information for beclomethasone dipropionate nasal spray

Eligibility and Restrictions for Use

Eligibility for Rhinomaxil (Beclometasone Dipropionate Nasal Spray)

Official regulatory documents define specific populations who are approved to use Rhinomaxil, as well as those for whom use is restricted or explicitly contraindicated. The medicine is generally approved for use in adults and children ge 6 years of age. Safety and effectiveness have not been established in children younger than 6 years and use is therefore not recommended in this age group.

Classification Population Eligibility Constraints (Official Labeling)
Absolute Contraindications Patients with known hypersensitivity or allergic reaction to beclometasone dipropionate or any of the product’s excipients.
Conditional Restrictions Use requires caution and supervision in patients with untreated localized nasal infection (e.g., fungal), recent nasal surgery, or nasal trauma until complete healing. Caution is also advised for those transferring from systemic (oral) steroid therapy.
Physiological Status Use during pregnancy or lactation is generally not recommended unless the potential benefit justifies the potential risk, as established safety data is limited.

Older adult patients typically require no specific dosage adjustment. Use is strictly limited to individuals where there is no evidence of active or quiescent tuberculosis or ocular herpes simplex due to the corticosteroid component. The criteria for use are based on governing agencies like the FDA and EMA.

What should I know about interactions with other medicines?

The documented interaction profile for Rhinomaxil (beclometasone dipropionate nasal spray) is centered on potential effects from co-administered medications that influence its systemic exposure, as defined by regulatory agencies.

Metabolic and Exposure-Altering Interactions

The primary documented pharmacokinetic concern involves strong CYP3A inhibitors, specifically Ritonavir and Cobicistat. Co-administration with these medicines may lead to a measurable increase in the systemic exposure of the corticosteroid component. Because beclometasone is less dependent on this metabolic pathway than some other steroid medications, generalized interactions are unlikely. However, regulatory authorities note that the possibility of systemic corticosteroid effects, such as hypercorticism or adrenal suppression, cannot be excluded during co-administration with these specific inhibitors.

Additive Pharmacodynamic Effects

An important pharmacodynamic interaction exists with other systemic or inhaled corticosteroids. The combined use of these products results in an additive systemic effect, increasing the overall glucocorticoid burden. This interaction is noted in prescribing information as a factor in monitoring the total steroid load.

Regulatory Classification and Restrictions

Official documentation does not contain mandatory dose separation rules or timing-based interaction requirements for co-administration. Furthermore, no drug-drug combination is formally classified as a contraindication due to an interaction mechanism, and no specific interactions with food, alcohol, or herbal supplements are documented in the official nasal spray labels.

Mechanism of Action

Rhinomaxil's mechanism of action is focused on modulating specific biochemical pathways involved in cellular signaling.

Primary Receptor Binding

Rhinomaxil functions as a selective inhibitor of the OPN-1 pathway by binding to the OPN-1 receptor complex. This high-affinity interaction initiates a blockade of ligand-receptor signaling, preventing the receptor's activation.

Intracellular Signaling Modulation

The resultant inhibition of the OPN-1 signaling cascade leads to a decrease in OPN-1 mediated local calcium-phosphate release. This action serves to directly modulate osteoclast activity at the cellular level.

Downstream Cytokine Regulation

Rhinomaxil further alters the downstream phosphorylation cascade of the NF-кB signaling module. This signal transduction interference leads to the nuclear exclusion of transcription factors. The compound ultimately downregulates the expression of the inflammatory cytokine, IL-6.

Dosage and Administration Information

Rhinomaxil, which contains the corticosteroid beclometasone dipropionate, is intended for intranasal use only and must be used as prescribed by a healthcare provider. The suspension acts locally to reduce inflammation and congestion in the nasal lining.

Proper Administration Technique

For optimal effectiveness and to minimize the risk of local side effects like nosebleeds, the spray should be administered correctly. This method ensures the medication is deposited on the lateral nasal wall, away from the delicate nasal septum.

Step Action for Each Nostril Key Detail
1. Preparation Gently shake the bottle and remove the cap. Prime the pump by spraying into the air until a fine mist appears if it's new or hasn't been used for several days.
2. Clear Nose Gently blow your nose to clear the nasal passages. This removes excess mucus that may block the medication.
3. Positioning Close the opposite nostril with a finger. Tilt your head slightly forward. Maintain the bottle upright and insert the nozzle tip slightly into the open nostril.
4. Spray Use the opposite hand to spray (e.g., right hand for the left nostril). Point the nozzle slightly outwards, away from the center ridge (septum).
5. Inhale & Press Breathe in gently through the nose while simultaneously pressing down firmly on the applicator to release the spray. Do not sniff hard, as this can cause the medication to run down the throat.
6. Repeat & Clean Repeat steps 3-5 if a second spray is required. Wipe the nozzle with a clean tissue and replace the cap. Avoid blowing your nose immediately after administration.

Dosage and Duration

The dosage of Rhinomaxil (Beclometasone) is highly individualized based on the patient's age and the severity of their symptoms. Generally, treatment starts with 1-2 sprays into each nostril twice daily. Never exceed the maximum dose prescribed by your physician. It is important to use the spray regularly for the full duration recommended by your doctor, even if symptoms improve quickly, as the full therapeutic effect may take up to two weeks.

Recent Clinical Evidence

The evidence base for Rhinomaxil (beclometasone dipropionate nasal spray) is primarily drawn from clinical trials and research summaries cited in official scientific literature. The product was studied in research that evaluated patient-reported outcomes related to discomfort and daily functioning. Findings describe group patterns under specific study conditions, and research contributes to describing what has been observed so far.


Evidence for Use in Seasonal Allergic Rhinitis

The foundation of the evidence for use in conditions characterized by fluctuating or episodic manifestations like Seasonal Allergic Rhinitis (SAR) is built on short-term, randomized controlled trials (RCTs). These studies were used to evaluate how symptoms change over time, typically over observation periods lasting two to six weeks. Researchers examined patient-reported outcomes describing perceived discomfort, such as the overall intensity of nasal congestion, sneezing, and a runny nose. Studies report how symptoms evolved in the observed populations, with findings describing patterns observed in the studies related to these outcomes linked to inflammatory or irritative states.


Evidence for Use in Persistent (Perennial) Allergic Rhinitis

For Perennial Allergic Rhinitis (PAR), which involves conditions presenting with cycles of stability and flare-ups throughout the year, the research explored longer observation intervals, typically six to twelve weeks, with some safety studies extending up to one year. This longer follow-up was utilized to assess outcomes related to systemic or functional imbalance in persistent symptoms. Data show patterns related to measurements of symptom scores over these intermediate periods. Findings help contextualize how patients reported their experience during long-term periods of observation.


Research Gaps and What Remains Uncertain

While long-term observational periods exist, the evidence indicates that long-term outcomes are not well characterized when discussing continuous evaluation beyond one year. Comparative evidence is lacking when placing this medicine directly against all other newer classes of localized rhinitis therapies. Furthermore, evidence quality varies across studies, particularly for less common evaluations, such as vasomotor rhinitis. Findings describe group patterns, and this evidence highlights what is known—and what is still uncertain—about this medicine’s evaluation in various patient circumstances.

Key Studies & References

  1. Beclomethasone Dipropionate Nasal Spray NIH DailyMed Information (Indications and Uses)
  2. Beclomethasone Nasal Spray Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Rhinomaxil (FAQ)


Q: Is Rhinomaxil an antibiotic or just a decongestant?

According to official product information, Rhinomaxil is a corticosteroid. This means it is an anti-inflammatory medicine that reduces swelling and prevents inflammation in the nasal passages. It is not classified as an antibiotic for bacterial infections, nor is it a simple decongestant that works by immediately narrowing blood vessels.


Q: Is Rhinomaxil the same as Xylometazoline, or is it different?

Rhinomaxil, which contains beclometasone, is a corticosteroid used for long-term inflammation management. This distinguishes it from medicines like Xylometazoline, which are decongestants that work by narrowing blood vessels. They have different purposes and mechanisms of action.


Q: Does Rhinomaxil work for allergy-related stuffiness?

Yes, official documentation indicates that Rhinomaxil is specifically approved for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, often known as hay fever. Its anti-inflammatory action is intended to address the symptoms of allergic rhinitis, such as stuffiness, sneezing, and runny nose.


Q: Why do some people say Rhinomaxil makes them feel jittery?

Official labeling notes that nasal corticosteroids, especially with prolonged use or higher than recommended doses, may rarely cause systemic side effects. These infrequent reactions can include symptoms like psychomotor hyperactivity, anxiety, or various sleep disturbances. Regulatory documents indicate these events are reported rarely.


Q: Does Rhinomaxil lose its effectiveness if used frequently?

Studies and official information indicate that the best therapeutic effect of Rhinomaxil is achieved with daily, regular use. Consistent application is required because the full benefit of reducing inflammation may take several days to appear. The labeling emphasizes the necessity of consistent, regular use to achieve its intended effect.


Q: Are there any serious, but rare, side effects linked to Rhinomaxil?

Regulatory documents describe that while rare, serious side effects have been reported. These include severe hypersensitivity reactions such as anaphylaxis (a serious allergic reaction) or generalized rash. There is also a potential for adrenal suppression, which is primarily a concern with long-term use at higher than recommended doses.


Q: Can Rhinomaxil interact with certain supplements, like St. John's Wort?

While official labels specifically warn about interactions with certain prescription medicines, official labels contain a general caution to review all medicines and supplements, including herbal products, with a healthcare provider. This is due to a lack of specific testing data on possible interactions with all supplements.


Q: What should I do if I miss a scheduled use of Rhinomaxil?

Official guidance states that a missed dose is generally taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, it is usually advised to skip the missed one. The labeling advises against taking extra sprays to make up for a missed application.


Q: How does Rhinomaxil affect the sinuses compared to a pill decongestant?

Rhinomaxil is applied directly into the nose and works locally on the nasal lining to reduce inflammation at the source. This targeted action allows it to provide anti-inflammatory effects with generally lower systemic exposure compared to an oral pill decongestant, which affects the entire body. This lower systemic exposure is a key distinction from oral medications.


Q: Does Rhinomaxil have a specific smell or taste?

Official regulatory records list reports of an unpleasant taste or unpleasant smell as adverse events experienced by some patients in clinical trials. If a persistent bad taste or smell is noticed, a review of the administration technique with a healthcare professional may be helpful.


Q: Can Rhinomaxil be used for a non-allergic runny nose?

Yes, regulatory documentation indicates that some formulations of the active ingredient, beclometasone, are approved for treating the symptoms of non-allergic rhinitis (also known as vasomotor rhinitis). This is in addition to its common indication for allergic rhinitis.


Q: Does Rhinomaxil help with post-nasal drip?

Rhinomaxil works to reduce inflammation and mucus production related to allergic rhinitis. By controlling symptoms like a runny nose and excess mucus, it is intended to address the underlying inflammatory causes that commonly contribute to post-nasal drip.


Q: Why might Rhinomaxil be preferred over an oral decongestant for some people?

Rhinomaxil is a topical nasal spray, meaning it acts locally at the site of inflammation. This delivery method typically results in lower absorption into the rest of the body compared to an oral medicine. The lower absorption into the body is a key distinction from oral medicine.


Q: Is Rhinomaxil safe to use during pregnancy or while breastfeeding?

Official labeling states that established safety data is limited regarding use during pregnancy or lactation. Therefore, use is generally not recommended unless the potential benefit is determined to outweigh the potential risks. Decisions regarding its use during pregnancy or lactation should be made in consultation with a healthcare provider.


Q: What age group is Rhinomaxil generally recommended for?

According to official drug labels, Rhinomaxil is generally indicated for use in adults and children 4 years of age and older. Safety and effectiveness have not been established in children younger than 4 years, and its use is not recommended for that age group.


Q: What happens if I accidentally swallow a little bit of Rhinomaxil?

After being sprayed into the nose, a portion of the medication is naturally swallowed. The systemic absorption of the drug is primarily driven by this swallowed portion, which is a key consideration in the drug's overall safety profile as assessed by regulatory bodies.

How should Rhinomaxil be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory agencies stipulate specific conditions for storing Rhinomaxil (Beclomethasone nasal spray/aerosol) to maintain its stability and effectiveness.

Condition Requirement
Temperature Store at controlled room temperature (e.g., 20 C to 25 C). Do not exceed 30 C.
Prohibited Do not freeze the container. Keep away from excessive heat and direct flame.
Protection Keep the container tightly closed and protect it from light and moisture.
Child Safety Keep the medication out of the reach of children.
Stability Discard the product after the labeled number of sprays has been reached, or when the dose counter reads zero, even if some contents remain.
Disposal Do not puncture the pressurized canister or dispose of it in fire. Unused or expired medication must be taken to a pharmacist or official drug take-back location; do not dispose of it in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rhinomaxil found in:

A-Z Index: